Psychometric evaluation of a visual analog scale for the assessment of anxiety

Abstract

BackgroundFast-acting medications for the management of anxiety are important to patients and society. Measuring early onset, however, requires a sensitive and clinically responsive tool. This study evaluates the psychometric properties of a patient-reported Global Anxiety - Visual Analog Scale (GA-VAS).MethodsData from a double-blind, randomized, placebo-controlled study of lorazepam and paroxetine in patients with Generalized Anxiety Disorder were analyzed to assess the reliability, validity, responsiveness, and utility of the GA-VAS. The GA-VAS was completed at clinic visits and at home during the first week of treatment. Targeted psychometric analyses—test-retest reliabilities, validity correlations, responsiveness statistics, and minimum important differences—were conducted.ResultsThe GA-VAS correlates well with other anxiety measures, at Week 4, r = 0.60 (p < 0.0001) with the Hamilton Rating Scale for Anxiety and r = 0.74 (p < 0.0001) with the Hospital Anxiety and Depression Scale - Anxiety subscale. In terms of convergent and divergent validity, the GA-VAS correlated -0.54 (p < 0.0001), -0.48 (p < 0.0001), and -0.68 (p < 0.0001) with the SF-36 Emotional Role, Social Function, and Mental Health subscales, respectively, but correlated much lower with the SF-36 physical functioning subscales. Preliminary minimum important difference estimates cluster between 10 and 15 mm.ConclusionsThe GA-VAS is capable of validly and effectively capturing a reduction in anxiety as quickly as 24 hours post-dose.

Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review

“…Cole and colleagues 401 argued that anchor values should be used in considering individual change, and for group-level change distribution (SEM) estimates were preferable to SES (0.5 SDs) estimates because the latter does not account for the internal consistency of the measurement being used. A study by Williams and colleagues 402 presented a wide range of values but then considered clustering of values within this range and reported the range within which values tended to cluster. Barber and colleagues 403 calculated 95% CIs for each of the methods used and, finding overlap, used an anchor estimate arguing that the distribution method estimate supported it.…”

Utility and validity of a single-item visual analog scale for measuring dental anxiety in clinical practice

“…DAS and VAS-A were strongly correlated, and the VAS-A (12) evaluated the psychometric properties of a patient-reported Global Anxiety VAS (GA-VAS) for measuring anxiety in clinical trials assessing pharmaceutical treatment for generalized anxiety disorders. They reported that the GA-VAS was reliable, responsive, and valid in assessing improvement in anxiety symptoms within 1 week of beginning administration of anxiolytic drugs (12).…”

A Modification of the Relative Weightings of Symptoms Utilizing a Logistic Function to Enhance the Linearity of the Brief Psychiatric Rating Scale: A Retrospective Analysis

“…This problem would be remedied by prospective research to obtain a normallydistributed data set. In relation to details of the form of the scales, we speculate that a more precise way approached from another viewpoint might be possible, for example, utilizing a visual analogue scale (VAS) [35][36][37][38][39] or a numerical rating scale (NRS) [40,41] for the ratings by psychiatrists, both of which range from 0 to 10, for the scores that we substituted for the clinical impression (although the true estimation of their validity is in flux at present [42][43][44][45][46][47][48]). We chose instead the ordinal CGI-SCH scores, which range ordinarily from 1 to 7 (taking "0" as "not assessed"), to express the clinicians' global impresssion of illness with schizophrenic patients.…”